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Sickle cell anemia (SCA) is a disorder characterized by a heterogeneous clinical outcome. In the present
study, we investigated the associations between Tumor Necrosis Factor-alpha (TNF-alpha) 308G>A and
Interleukin 8 (IL-8) 251A>T gene polymorphisms, medical history and classical biomarkers in children
with steady-state SCA. In total, 210 SCA patients aged 2–21 years and 200 healthy controls were studied.
Gene polymorphisms, betaS-globin haplotypes and a 3.7-kb deletion in alpha2-thalassemia (a2-thal3.7 kb)
were investigated by PCR/RFLP analysis, and cytokine levels were determined by ELISA. Splenomegaly
(p = .032) was more prevalent among children younger than 5 years of age. The A allele of the TNF-alpha
308G>A gene polymorphism and the presence of a2-thal3.7 kb were associated with an increase risk of
splenic sequestration events (p = .001; p = .046), while the T allele of the IL-8 251A>T gene polymor-
phism was considered to be a protective factor for splenomegaly events (p = .032). Moreover, the A allele
of the TNF-alpha 308G>A gene polymorphism was associated with high TNF-alpha levels (p = .021), and
the hemoglobin F and hemoglobin S haplotypes were correlated with serum levels of IL-8. The logistic
regression analysis showed signiﬁcant effects of the TNF-alpha and IL-8 gene polymorphisms, betaS-globin
gene haplotypes and a2-thal3.7 kb on the occurrence of splenic sequestration events. Our study empha-
sizes that the identiﬁcation of new genetic and immunological biomarkers and their associations with
classical markers is an important strategy to elucidate the underlying causes of different SCA phenotypes
and their effects on patient outcome.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Sickle cell anemia (SCA) is an inherited recessive autosomal
disorder characterized by clinical heterogeneity that may be inﬂu-
enced by environmental factors, ethnicity, social and economic
factors and genetic markers secondary to epigenetic phenomena.
These genetic factors include associations between SCA and
betaS-globin haplotypes, the presence of a 3.7-kb deletion in
alpha2-thalassemia (a2-thal3.7 kb) and fetal hemoglobin concentra-
tion, which is a well-known prognostic marker [1].
Clinical manifestations of SCA are based on vaso-occlusive epi-
sodes that impair blood ﬂow as a consequence of intravascular
sickling in capillaries, hemolysis, cellular activation, leukocytosisnçalo Moniz – Laboratório de
mar Falcão 121 Brotas, CEP:
5 71 3176 2226.
lves).
ipt.
sevier OA license.and the breakdown of homeostasis [2–4]. The major clinical fea-
tures include pain, stroke, priapism, acute chest syndrome, osteo-
necrosis and renal failure [5].
The betaS-globin gene haplotypes have been shown to correlate
with the clinical features of SCA patients; the CAR haplotype may
be associated with more severe symptoms, while the SEN haplo-
type correlates with a better prognosis [6–8]. The concurrent
a2-thal3.7 kb is correlated with protection against the hemolysis-
associated phenotypes of leg ulcers and priapism [9] and is
associated with increased risk for the viscosity-vaso-occlusive phe-
notypes of acute pain and osteonecrosis [10,11]. Despite a common
genetic background, the phenotypic expression in SCA patients
varies widely, from mild clinical symptoms with survival into
60–70 years of age to very severe clinical symptoms with multi-or-
gan damage and early mortality [6,12].
TNF-alpha and IL-8 are pro-inﬂammatory molecules involved in
endothelial cell and leukocyte activation, macrophage stimulation,
afﬁnity of leukocyte surface molecules and endothelial receptors
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anemia patients have increased serum levels of circulating TNF-al-
pha and IL-8 at steady state and during crisis events [17,18]; these
inﬂammatory molecules also possibly contribute to the complex
mechanisms involved in vascular occlusion events. Thus, aberra-
tions in cell activation and interaction, the pro-inﬂammatory and
oxidant proﬁles, genetic background and environmental factors
possibly result in recurrent vascular events [19,20].
Changes in the cytokine balance in SCA patients are an impor-
tant risk factor for the occurrence of clinical events [21]. Moreover,
inter-patient variations in cytokine levels could be attributed to
gene polymorphisms, notably the A alleles of -308 G>A and 251
A>T, which are positioned in the promoter regions of the TNF and
IL-8 genes, respectively, and have been associated with higher
TNF-alpha and IL-8 transcript levels [22,23].
Based on these observations, the present study investigated
polymorphisms in the TNF-alpha and IL-8 genes and their associa-
tion with the respective cytokine serum levels, medical history and
classical biomarkers presented by SCA patients.Table 1
Clinical features of the sickle cell anemia patients.
Clinical proﬁle Frequency Percent
Vaso-occlusive events 180/210 85.7
Pneumonia 75/210 35.7
URTI 40/210 19.0
Splenic sequestration 23/210 10.9
Splenomegaly 19/210 9.0
Stroke 11/210 5.2
Urinary infection 8/210 3.8
Osteonecrosis 3/210 1.4
Leg ulcer 1/210 0.5
URTI: upper respiratory tract infection.2. Materials and methods
2.1. Subjects
A cross-sectional study comprising 210 SCA children (123 male
and 87 female; 9.3 ± 4.5 years) selected from the hematology outpa-
tient clinic of theHematologyandHemotherapyFoundationof Bahi-
a State (HEMOBA) was performed. The samples were collected
during the period from 2003 to 2007. Clinical data were collected
from the patients’ medical records, and demographic data were ob-
tained by interviews with patients and their parents or guardians.
Only pediatric SCA patients were eligible. All patients were at the
steady state of the disease, which was characterized as a period of
three months without any acute events and no blood transfusions
for 120 days prior to blood sampling. Exclusion criteria included
thepresenceof infectiousdiseases, hemoglobinproﬁles not compat-
ible with SCA, previous blood transfusions (less than four months
before the study) and inﬂammatory episodes during the study.
The study was approved by the Gonçalo Moniz Research Center
of the Oswaldo Cruz Foundation (FIOCRUZ) Ethics Committee, and
all parents or guardians provided written informed consent fol-
lowed by the children’s agreement, in accordance with the Decla-
ration of Helsinki of 1975, as revised in 2000. Clinical
information was collected from the patients’ charts and their
physicians.
The control group consisted of 200 individuals who attended
the clinical laboratory of the Pharmacy College of the Federal Uni-
versity of Bahia (UFBA), and these individuals were age- and sex-
matched with the SCA patients group. The control individuals
had normal hemoglobin proﬁles and lacked a history of anemia,
inﬂammatory conditions and hematological diseases.
2.2. Hematological and hemoglobin analyses
Hematological analyses were performed using an electronic cell
counter (Coulter Counter T890, Brea, CA, USA). The hemoglobin
proﬁle was analyzed by high-performance liquid chromatography
(HPLC) (Bio-Rad Variant, CA, USA).
2.3. BetaS-globin gene haplotypes and a 3.7-kb deletion in alpha-2-
thalassemia
DNA was isolated from blood leukocytes using the GFXTM Geno-
mic Blood DNA Puriﬁcation Kit (Amersham Pharmacia Biotech, NJ,
USA). The betaS-globin gene haplotypes and a2-thal3.7 kb wereinvestigated with PCR and restriction fragment length polymor-
phism (RFLP) techniques as previously described [24,25].
2.4. Typing of single nucleotide polymorphisms (SNPs) and
measurement of serum cytokine levels
The TNF-alpha 308G>A and IL-8 251A>T gene polymor-
phisms were investigated with PCR and RFLP techniques as previ-
ously described [26,27].
Serum TNF-alpha and IL-8 levels were measured with an en-
zyme-linked immunosorbent assay (ELISA) (BD Biosciences Pharm-
ingen, USA), according to the manufacturer’s instructions, with
cut-off levels of 67.8 pg/mL and 615.0 pg/mL for TNF-alpha and
IL-8, respectively.
2.5. Statistical analysis
The baseline characteristics are presented as the means and
proportions of the selected variables. The distributions of quantita-
tive variables were determined using the Kolmogorov–Smirnov
test. Bivariate correlation analysis was performed to determine
correlations between pairs of variables using Spearman’s rho cor-
relation. Parametric ANOVA analyses conﬁrmed by Bonferroni post
hoc tests and the nonparametric Kruskal–Wallis tests were used to
compare the means among two or more groups of interval vari-
ables that were normally distributed and not normally distributed,
respectively. Interactions between speciﬁc categories of clinical
variables were tested for signiﬁcance using a v2 test corrected by
Yates or Fisher’s exact test, and the expected frequency in the cell
tables was taken into account.
The logistic regression was applied to test several models com-
pounded by variables associated with splenic sequestration epi-
sodes. The independent variables were TNF-alpha 308G>A, IL-8 
251A>T, Gender, a2-thal3.7 kb and the betaS-globin haplotypes.
The data analysis was performed using EPI Info 6.04 (CDC,
Atlanta, Georgia), Statistical Data Analysis (STATA) SE 10 (Stata-
Corp, Texas, USA) and GraphPad Prism 5.0. A p-value of less than
.05 was considered statistically signiﬁcant.3. Results
Our study included a total of 210 SCA patients aged 2–21 years,
36.6% of which were female. Clinical features are described in Ta-
ble 1. Vaso-occlusive pain episodes occurred in patients of all ages,
and splenomegaly was more prevalent among children younger
than 5 years of age (Fig. 1).
3.1. Alpha2-thalassemia 3.7-kb deletion and betaS-globin gene
haplotypes
Frequencies of a2-thal3.7kb and the betaS-globin gene haplotypes
in the SCA group are described in Table 2.
Fig. 1. Splenomegaly incidence among SCA patient of different ages. P⁄ ANOVA.
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polymorphisms
The IL-8 251A>T and TNF-alpha 308G>A gene polymorphism
frequencies of the 210 patients and the 200 individuals in the ref-
erence group were analyzed. The genotype frequencies were in
Hardy–Weinberg equilibrium (Table 3).
3.3. Associations between the TNF-alpha 308G>A and IL-8 251A>T
gene polymorphisms, betaS-globin gene haplotypes and alpha2-thalas-
semia 3.7-kb deletion and clinical events in children with sickle cell
anemia
The A allele of the TNF-alpha gene polymorphism and the pres-
ence of a2-thal3.7 kb were associated with splenic sequestration epi-
sodes (Table 4). The T allele of the IL-8 gene polymorphism was
characterized as a protection factor for splenomegaly (OD: 0.326;
95% CI: 0.114–0.937; P = 0.032).
3.4. Serum levels of IL-8 and TNF-alpha
The mean serum IL-8 level was 10.90 ± 13.13 pg/mL with a min-
imum of 1.67 and a maximum of 109.05 pg/mL. The mean serum
TNF-alpha level was 29.71 ± 19.49 pg/mL with a minimum of
1.30 and a maximum of 128.41 pg/mL. The presence of the AG
and AA genotypes of the 308G>A TNF-alpha gene polymorphism
was associated with the highest serum levels of TNF (p = .021)
(Fig. 2). The presence of the AT and TT genotypes of the 251A>T
IL-8 gene polymorphism was not associated with serum levels of
IL-8.
3.5. Hemoglobin proﬁles and IL-8 serum levels
Fig. 3 shows the positive correlation between IL-8 and HbS and
the negative correlation between this cytokine and HbF.Table 2
Frequencies of classical genetic prognosis markers.
Frequency Percent
a2-thal3.7 kb
Heterozygous 37/174 21.3
Homozygous 2/174 1.1
betaS-globin haplotypes
CAR/CAR 41/210 19.5
CAR/BEN 98/210 46.7
CAR/atypical 5/210 2.4
CAR/CAM 2/210 0.9
BEN/BEN 52/210 24.8
BEN/atypical 7/210 3.3
BEN/CAM 5/210 2.43.6. Multivariate associations of independent markers, such as the
TNF-alpha 308G>A and IL-8 251A>T gene polymorphisms, betaS-
globin gene haplotypes, and alpha-2 thalassemia 3.7-kb deletion, and
splenic sequestration in children with sickle cell anemia
Models show the possible interactions between independent
variables and their inﬂuences on dependent variables, such as sple-
nic sequestration, and were adjusted for age and gender.
Presence of the TNF-alpha gene polymorphism and a2-thal3.7 kb
are independently related to the risk of splenic sequestration
events. In the ﬁrst model, patients with these genetic modiﬁcations
have a decreased risk of this clinical phenotype. Moreover, we ob-
served in the third model that patients with TNF-alpha gene poly-
morphisms, a2-thal3.7 kb and IL-8 gene polymorphisms had a
decreased risk of splenic sequestration. However, males with the
CAR haplotype in the second and fourth models had an increased
risk of splenic sequestration events (Table 5).4. Discussion
The presentation and clinical course of sickle cell anemia show
substantial viability between patients, from sporadic pain crises to
organ damage, resulting in frequent hospitalization and early
death [28].
The data presented herein demonstrate that vaso-occlusive pain
episodes are found among patients of different ages, which con-
ﬁrms that these clinical events occur in all age groups. Moreover,
the occurrence of splenomegaly was more prevalent among chil-
dren younger than 5 years of age in the SCA patients studied. This
result agrees with previous reports that describe children from the
United States of America and emphasizes the ﬁnding that spleens
from children with SCA progress through several changes and that
dysfunction begins very early in infancy [2,6,29–31].
Several genetic association analyses have been performed to
link single nucleotide polymorphisms or deletions with particular
complications of sickle cell anemia [32–35]. a2-thal3.7 kb is fre-
quently present in SCA patients and correlates with clinical proﬁles
because its occurrence is related to an increase in hemoglobin con-
centration, a decrease in hemoglobin S polymerization and a
reduction in hemolysis. The clinical effects of a2-thal3.7 kb are var-
iable but are usually beneﬁcial for patients, such as reductions in
the occurrence of stroke [36], gall stones [37], leg ulcers [38] and
priapism [39], which are based on the decrease in hemolysis; how-
ever, pain frequency is not reduced because there is an increase in
blood viscosity [30]. Our results show that splenic sequestration is
partly attributable to the presence of a2-thal3.7 kb. The high hemat-
ocrit and increased blood viscosity generated by a2-thal3.7 kb could
promote morphological sickling and lead to a lack of deformability,
both of which are important etiological factors for splenic seques-
tration [30,40].
The association between the A allele of the TNF-alpha gene and
splenic sequestration was observed; patients with the mutant
genotype have a 4.6-fold increased risk for the development of this
clinical manifestation. Other studies that correlated the A allele of
the TNF-alpha gene and clinical events are controversial. Hoppe
et al. [32] ﬁrst identiﬁed a protective role of the A allele of the
TNF-alpha gene using a logistic regression model with many inde-
pendent variables related to large vessel stroke. Hoppe et al. [33]
conﬁrmed the role of the A allele of the TNF-alpha gene as a protec-
tive factor for large vessel stroke. However, Vicari et al. [35] did not
ﬁnd an association between the mutant allele of the TNF gene and
stroke.
TNF-alpha, which is mainly produced by macrophages and T
cells, is a potent cytokine with a wide range of pro-inﬂammatory
activities, including the activation of endothelial cells; stimulation
Table 3
Frequencies of IL-8 251A>T and TNF-alpha 308G>A gene polymorphisms in children with steady-state sickle cell anemia compared with the healthy control group.
Cytokine
genotype
Genotype frequency N (%)
SCA Healthy control
IL-8
251A>T
AA 31 (14.8) 28 (14.0) P = 0.68a
OD:0.89
95% CI: 0.49–1.61
AT 108 (51.4) 98 (49.0)
TT 71 (33.8) 74 (37.0)
Total 210 200
TNF-alpha
308G>A
GG 162 (77.1) 146 (73.0) P = 0.28a
OD: 0.78
95% CI: 0.49–1.25
GA 46 (21.9) 50 (25)
AA 2 (1.0) 4 (2.0)
Total 210 200
The genotypic and allelic distributions of all polymorphisms were in Hardy–Weinberg equilibrium.
a v2.
Table 4
Associations of clinical variables with TNF-alpha 308G>A and IL8 251A>T gene polymorphisms, CAR/CAR and CAR/BEN betaS-globin gene haplotypes and the 3.7-kb deletion of
alpha-2 thalassemia among children with steady-state sickle cell anemia.
Vaso-occlusive events Pneumonia Splenic sequestration Stroke URTI Urinary infection
IL-8 251A>T
AA 26/31 11/31 4/31 1/31 7/31 1/31
AT + TT 154/179
OR = 1.18,b
95% CI:0.41–3.37
P = .75
64/173
OR = 1.06,a
95% CI:0.48–2.37
P = .87
19/179
OR = 0.80,b
95% CI:0.25–2.53
P = .70
10/179
OR = 1.77,b
95% CI:0.21–14.38
P = .59
33/179
OR = 0.77,b
95% CI:0.38–1.95
P = 0.58
7/179
OR = 1.22,b
95% CI:0.14–10.28
P = 0.85
TNF 308G>A
GG 141/162 60/156 11/162 10/162 30/162 7/162
GA + AA 40/48
OR = 0.78,a
95% CI:0.32–1.88
P = .58
15/48
OR = 0.73,a
95% CI:0.37–1.46
P = .38
12/48
OR = 4.60,a
95% CI:1.88–11.27
P = .001
1/48
OR = 0.34,b
95% CI:0.04–2.60
P = .29
10/48
OR = 1.16,a
95% CI:0.52–2.60
P=.70
1/48
OR = 0.47,b
95% CI:0.05–4.00
P = .49
Haplotypes
CAR/CAR 38/41 14/39 4/41 5/41 5/41 1/41
CAR/BEN 80/97
OR = 0.37,a
95% CI:0.10–1.34
P = .13
34/95
OR = 0.99,a
95% CI:0.46–2.16
P = .099
12/97
OR = 1.30,b
95% CI:0.39–4.31
P = .66
3/93
OR = 0.23, a
95% CI:0.52–1.01
P = .052
16/97
OR = 1.42,b
95% CI:0.48–4.18
P = 0.52
3/97
OR = 1.28,b
95% CI:0.13–12.65
p = 0.83
Alpha-2-Thalassemia 3.7 kb
Wild type 110/134 49/129 12/134 7/134 29/134 5/134
Heterozygous/Homozygous 35/38
OR = 2.55,a
95% CI:0.72–8.96
P=.14
18/37
OR = 1.55,a
95% CI:0.74–3.23
P=.24
8/38
OR:2.71,a
95% CI:1.02–7.22
P=.046
3/38
OR = 1.55,b
95% CI:0.38–6.32
P=.53
7/38
OR:0.82,a
95% CI:0.33–2.05
P=.67
1/38
OR = 0.70,b
95% CI:0.08–6.15
P = 0.75
OR: odds ratio; URTI: upper respiratory tract infection.
a v2 Yates corrected.
b Fisher’s exact test.
Fig. 2. TNF-alpha 308G > A gene polymorphism and serum cytokine levels in
children with steady-state sickle cell anemia. ⁄Spearman’s Correlation.
C. Cajado et al. / Cytokine 56 (2011) 312–317 315of inﬂammation; induction of the coagulation cascade, fevers and
the synthesis acute phase proteins; activation of neutrophils; and
stimulation of neutrophil adhesion [15]. These characteristics
make serum TNF levels an important risk factor in SCA. Lanaro
et al. [17] observed an increase in the circulating levels and an in-
crease in mRNA expression of TNF-alpha in SCA patients at steady
state, which is characteristic of a pro-inﬂammatory state. More-
over, Pathare et al. [21] observed an increase in the circulating con-
centration of TNF-alpha during crisis events. In our study, we
observed an association between the A allele of TNF-alpha
308G>A and an increase in the serum levels of TNF-alpha in
SCA patients. Another study observed that an increase in the serum
levels of TNF-alpha was associated with the A allele of TNF-alpha
308G>A [41]. Using a reporter gene assay, Wilson et al. [22] sug-
gested that the A allele of TNF-alpha 308G>A affects transcrip-
Fig. 3. Hemoglobin proﬁle and serum IL-8 levels in children with steady-state
sickle cell anemia.
316 C. Cajado et al. / Cytokine 56 (2011) 312–317tional activity and results in an increase in the expression of the
TNF gene.
However, this is the ﬁrst study that assessed the impact of the
251A>T IL-8 gene polymorphism on the clinical phenotypes of
SCA patients; the splenomegaly protection of the T allele of
251A>T IL-8 gene could be related to its transcriptional activity
[23].These aspects indicate that the A allele of the TNF-alpha gene
and the T allele of the 251A>T IL-8 gene are important clinical
predictors of SCA.
The data presented in our study demonstrate a positive correla-
tion between IL-8 and S hemoglobin and an inverse correlation
with F hemoglobin. These results support a previous report in
which high IL-8 levels and other pro-inﬂammatory markers were
associated with SCA in patients during vascular occlusion episodes
(regardless of the crisis-inducing factor) and in steady-stateTable 5
Coefﬁcients, standard errors, P values, and conﬁdence intervals for SCA patients with sple
Variable Coefﬁcient Standard error P-value Odds rat
Model 1
TNF 1.1425 0.5091 0.0248* 3.1347
TALA 0.9955 0.5192 0.0552 2.7061
Model 2
TNF 1.4075 0.6715 0.0361* 4.0859
TALA 1.6353 0.6976 0.0191* 5.1308
HAPLO 0.2365 0.7759 0.7575 1.2668
GENDER 0.8709 0.7611 0.2525 2.3890
Model 3
TNF 1.1440 0.5091 0.0246* 3.1393
TALA 1.0020 0.5198 0.0539 2.7237
IL-8 0.2022 0.6922 0.7702 0.8169
Model 4
TNF 1.4072 0.6717 0.0362* 4.0844
TALA 1.6339 0.7015 0.0199* 5.1238
HAPLO 0.2380 0.7701 0.7573 1.2686
IL-8 0.0161 0.8679 0.9852 1.0162
GENDER 0.8765 0.7657 0.2545 2.3928
Models: TNF: TNF-alpha 308G>A; TALA: alpha-2-thalassemia with 3.7-kb deletion; HA
* p values in bold show signiﬁcant variables that are contributing to the dependent varpatients [17]. High serum levels of IL-8 are a marker of poor prog-
nosis based on their association with an increase in S hemoglobin
and decrease in F hemoglobin in red blood cells due to an increase
in intravascular hemolysis and increases in oxidative damage, cel-
lular activation, vascular occlusion and consequently inﬂamma-
tion, which characterize hemolysis, vascular occlusion and
inﬂammation as cyclical events in SCA.
Logistic regression results were obtained by multivariate asso-
ciation of classical biomarkers, such as CAR betaS-globin haplo-
types, the presence of a2-thal3.7 kb, the A allele of the TNF-alpha
gene and the T allele of the IL-8 gene, with splenic sequestration
events. The models show that the risk of occurrence of spleen
sequestration varies and depends on genetic abnormalities present
in each patient and gender. The most interesting observation in the
second and fourth models was that the inclusion of the CAR haplo-
type, a classical factor of poor prognosis [8], consequently
increased the risk of spleen sequestration.5. Conclusions
The results presented here indicate the importance of the A al-
lele of the TNF gene and the T allele of the 251A>T IL-8 in the clin-
ical events of SCA and further highlights the contribution of genetic
modiﬁcations to the risk of clinical phenotypes. Our study empha-
sizes that the identiﬁcation of new genetic and immunological bio-
markers and their association with classical markers is an
important strategy for the elucidation of different SCA phenotypes
and their effects on patient outcome. Further studies should be
performed to investigate the mechanisms by which these gene
polymorphisms affect clinical manifestations and the contribution
of these associations to the expression of cytokines and adhesion
molecules.
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